Disclaimer: This information is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Clinical judgment is paramount, and treatment decisions must always be tailored to the individual patient's presentation, comorbidities, and preferences. Drug dosages and treatment protocols may vary based on local guidelines and individual patient factors.

UGI Bleed Variceal

Overview

• Definition: Upper gastrointestinal (UGI) bleeding from varices refers to hemorrhage from abnormally dilated veins (varices) in the esophagus or stomach, which develop as a consequence of portal hypertension. This is a life-threatening complication of liver cirrhosis and other causes of portal hypertension.
• Epidemiology:
  • Variceal bleeding accounts for approximately 10-20% of all UGI bleeds.
  • It is a major complication of cirrhosis, with varices developing in about 50% of patients with compensated cirrhosis over 10 years, and in 80% of patients with decompensated cirrhosis.
  • The annual risk of a first variceal bleed is 5-15% for patients with large varices.
  • Mortality from a first variceal bleed remains significant, ranging from 15-20% at 6 weeks, despite advances in management.
  • Recurrence risk is high (60% within one year) if not adequately prevented.
• Classification:
  • Location:
    • Esophageal Varices: Most common site (90%). Graded based on size during endoscopy:
      • Small: Protruding slightly into lumen, flatten with insufflation.
      • Medium: Protruding into lumen, not obliterating lumen.
      • Large: Obliterating lumen, often coalescent.
    • Gastric Varices (GVs): Occur in 5-30% of patients with portal hypertension. Classified by the Sarin classification:
      • Gastro-Esophageal Varices (GOV):
        • GOV1: Extend along the lesser curve from the esophagus to the cardia.
        • GOV2: Extend along the greater curve from the esophagus to the fundus.
      • Isolated Gastric Varices (IGV):
        • IGV1: Located in the fundus only.
        • IGV2: Located in ectopic sites (duodenum, jejunum, colon, peritoneum).
  • Risk for Bleeding: Endoscopic signs predicting increased risk of bleeding include red wale marks, hematocystic spots, and large variceal size.

Pathophysiology

• Mechanism:
  1. Portal Hypertension: The primary driver. Increased resistance to portal blood flow (usually due to cirrhosis, less commonly pre-hepatic or post-hepatic causes) leads to an elevation in portal venous pressure (>10-12 mmHg, known as the hepatic venous pressure gradient [HVPG]).
  2. Portosystemic Collateral Formation: To decompress the portal system, collateral vessels develop, bypassing the liver. These occur at sites where the portal and systemic circulations meet, most commonly in the submucosa of the esophagus and gastric cardia/fundus.
  3. Variceal Formation and Dilation: Increased flow and pressure in these collateral veins cause them to dilate and become tortuous, forming varices.
  4. Rupture: Variceal rupture occurs when the transmural pressure (pressure inside the varix minus pressure outside) exceeds the wall tension. Factors contributing to rupture include:
     • High portal pressure (HVPG >12 mmHg).
     • Increased variceal size and wall tension (Laplace's Law).
     • Thinning of the variceal wall, erosions from gastric acid or reflux esophagitis.
     • Increased intra-abdominal pressure (e.g., vomiting, coughing).
  5. Coagulopathy: Patients with liver cirrhosis often have impaired hepatic synthesis of clotting factors and thrombocytopenia, exacerbating bleeding and making hemostasis difficult.
• Risk Factors:
  • Severity of Liver Disease: Child-Pugh class B or C, MELD score >18.
  • Presence and Size of Varices: Large esophageal varices or large gastric varices (especially fundal).
  • Endoscopic Stigmata: Red wale marks (longitudinal red streaks), cherry red spots, diffuse redness, hematocystic spots on varices.
  • High Hepatic Venous Pressure Gradient (HVPG): HVPG >12 mmHg is the threshold for variceal formation; >16 mmHg is associated with high bleeding risk.
  • Active Alcoholism: Continued alcohol use in cirrhotic patients increases bleeding risk.
  • Bacterial Infection: Associated with increased risk of first bleed and re-bleed.
  • Renal Impairment: Worsens outcomes.
  • Prior Variceal Bleed: Highest risk factor for rebleeding.
• Protective Factors:
  • Non-selective Beta-Blockers (NSBBs): Reduce portal pressure by decreasing cardiac output and splanchnic vasoconstriction.
  • Endoscopic Variceal Ligation (EVL): Obliterates varices, reducing rebleeding risk.
  • Transjugular Intrahepatic Portosystemic Shunt (TIPS): Directly decompresses the portal system.
  • Treatment of Underlying Liver Disease: Halting or reversing liver disease progression can reduce portal hypertension.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Hematemesis: Vomiting of fresh red blood or "coffee-ground" material (partially digested blood). This is the most common presentation.
  • Melena: Black, tarry, foul-smelling stools, indicating digestion of blood in the UGI tract.
  • Hematochezia: Passage of fresh red blood per rectum. Less common with variceal bleeding, but can occur with massive, rapid UGI bleeding and rapid transit.
• Early Signs:
  • Lightheadedness, dizziness, presyncope.
  • Weakness, fatigue.
  • Abdominal discomfort or pain.
  • Symptoms of anemia (e.g., dyspnea on exertion).
• Advanced Signs:
  • Hemodynamic Instability: Tachycardia (>100 bpm), hypotension (systolic BP <100 mmHg), orthostatic changes.
  • Hypovolemic Shock: Severe hypotension, cool and clammy skin, altered mental status.
  • Signs of Liver Decompensation:
    • Hepatic encephalopathy (confusion, lethargy, asterixis).
    • Ascites (increased abdominal distension).
    • Jaundice (new or worsening).
    • Coagulopathy (easy bruising, petechiae).
• Atypical Presentations:
  • Occult gastrointestinal bleeding with iron deficiency anemia.
  • Isolated melena without hematemesis.
  • Decompensation of liver disease (e.g., new-onset encephalopathy) triggered by a bleed, with bleeding signs being subtle.

Physical Examination

• Inspection:
  • Stigmata of Chronic Liver Disease: Jaundice (scleral icterus), spider angiomata, palmar erythema, gynecomastia, testicular atrophy (in males), hair loss.
  • Signs of Decompensation: Ascites (distended abdomen), peripheral edema.
  • Pallor: Indicative of anemia.
  • Altered Mental Status: From hepatic encephalopathy or hypovolemic shock.
• Palpation:
  • Splenomegaly: Common in portal hypertension.
  • Hepatomegaly/Liver size: Liver may be enlarged, nodular, or shrunken depending on the stage and etiology of cirrhosis.
  • Abdominal Tenderness: Usually non-specific, but may indicate peritonitis if spontaneous bacterial peritonitis (SBP) is present.
• Special Tests:
  • Rectal Examination: Essential to assess for melena or hematochezia, and to rule out other causes of lower GI bleeding.
  • Vital Signs: Frequent monitoring for tachycardia, hypotension, and orthostatic changes to assess hemodynamic stability.

Diagnostic Approach

History Taking

• Key Questions:
  • History of Liver Disease: Known cirrhosis, hepatitis (viral, alcoholic, NAFLD), autoimmune hepatitis, hemochromatosis, etc.
  • Previous UGI Bleed: History of variceal bleed, peptic ulcer disease, Mallory-Weiss tear.
  • Alcohol Consumption: Quantity and duration.
  • Medications: Anticoagulants, antiplatelets (aspirin, clopidogrel), NSAIDs (can precipitate bleeding or ulceration).
  • Onset and Characteristics of Bleeding: When did it start? How much blood? Fresh red, coffee-ground, or melena? Any clots?
  • Associated Symptoms: Lightheadedness, syncope, abdominal pain, fever, altered mental status, jaundice, ascites.
  • Comorbidities: Heart disease, renal disease, diabetes.
• Red Flags:
  • Massive hematemesis.
  • Hemodynamic instability (systolic BP <90 mmHg, heart rate >100 bpm, altered mental status, cool extremities).
  • Signs of hepatic encephalopathy.
  • Signs of acute liver decompensation.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Hemoglobin (Hb), hematocrit (Hct) to assess acute blood loss and baseline anemia; platelet count (thrombocytopenia common in cirrhosis).
  • Coagulation Profile: Prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) to assess synthetic liver function and coagulopathy.
  • Liver Function Tests (LFTs): Bilirubin (total and direct), AST, ALT, alkaline phosphatase, albumin to assess severity of liver disease (Child-Pugh, MELD score calculation).
  • Renal Function Tests: Blood urea nitrogen (BUN) and creatinine (Cr) to assess for acute kidney injury (common in massive UGI bleeding and particularly in cirrhosis due to hepatorenal syndrome risk). BUN/Cr ratio >20:1 may suggest UGI bleeding.
  • Electrolytes: Sodium, potassium.
  • Type and Cross-Match: Essential for potential blood transfusions.
  • Blood Ammonia: If hepatic encephalopathy is suspected.
  • Lactate: To assess for tissue hypoperfusion/shock.
• Confirmatory:
  • There is no specific lab test to confirm variceal bleeding. Diagnosis is confirmed by endoscopy.
• Monitoring:
  • Serial CBCs: Every 4-6 hours initially, then less frequently once stable, to monitor transfusion needs and bleeding control.
  • Serial Vitals: Continuous monitoring of heart rate, blood pressure, SpO2.
  • Renal Function/Electrolytes: Monitor for HRS, electrolyte imbalances.
  • Coagulation Profile: Monitor response to factor replacement.

Imaging

• Recommended:
  • Emergent Upper Endoscopy (Esophagogastroduodenoscopy - EGD): Gold standard for diagnosis and simultaneous therapeutic intervention. Should be performed within 12 hours of presentation after initial resuscitation.
    • Findings: Identification of esophageal or gastric varices, presence of active bleeding (spurting, oozing), white nipple sign (fibrin plug), or red wale marks, differentiating from other UGI bleed sources (ulcers, Mallory-Weiss tears).
• Advanced:
  • Computed Tomography Angiography (CTA): May be considered if endoscopy is inconclusive, technically difficult, or if there is massive, ongoing bleeding that obscures endoscopic visualization or prevents adequate control. Can help localize the bleeding site, identify vascular anomalies, or guide interventional radiology procedures.
  • Doppler Ultrasound of the Portal System: Not for acute diagnosis of bleeding, but useful in identifying portal hypertension, assessing portal vein patency, flow direction, and splenic vein thrombosis.
  • Hepatic Venous Pressure Gradient (HVPG) Measurement: Invasive procedure, typically reserved for research or specific clinical situations, not for acute bleeding management.

Management

Acute Management

The immediate goals are hemodynamic stabilization, control of bleeding, and prevention of complications. - Immediate (First Hour Interventions): 1. Airway Management: Assess for need for endotracheal intubation, especially in patients with massive hematemesis, encephalopathy, or impaired consciousness, to prevent aspiration. 2. Resuscitation: * Establish two large-bore intravenous (IV) lines (16-18 gauge). * Initiate fluid resuscitation with crystalloids (e.g., normal saline or lactated Ringer's) to restore circulating volume. Caution: Avoid aggressive over-resuscitation, which can increase portal pressure and worsen bleeding. Goal is to achieve hemodynamic stability (systolic BP 90-100 mmHg, heart rate <100 bpm), not normalize parameters completely. * Blood Transfusion: Transfuse packed red blood cells (pRBCs) to maintain hemoglobin levels between 7-8 g/dL. In patients with significant cardiovascular disease, a target of 8-9 g/dL may be appropriate. * Coagulopathy Correction: * Fresh Frozen Plasma (FFP): Consider for INR >1.5-2.0 in actively bleeding patients, especially those undergoing invasive procedures, but routine prophylactic FFP is not recommended. * Platelets: Transfuse if platelet count is <50,000/µL in actively bleeding patients or those undergoing invasive procedures. 3. Pharmacological Therapy: * Vasoactive Drugs: Administer promptly upon suspicion of variceal bleeding, before endoscopy. These drugs reduce splanchnic blood flow and portal pressure. Continue for 2-5 days post-hemostasis. * Octreotide: Somatostatin analog. * Dose: Bolus 50 mcg IV, followed by continuous infusion of 50 mcg/hour IV. * Terlipressin: Vasopressin analog (available in some regions, not FDA approved in the US for variceal bleeding but often used globally). * Dose: 2 mg IV every 4 hours for 48 hours, then 1 mg IV every 4 hours. Caution: Contraindicated in patients with ischemic heart disease. * Antibiotic Prophylaxis: Crucial for all patients with suspected variceal bleeding, as bacterial infections (e.g., SBP, pneumonia, UTI) are common and increase mortality and rebleeding risk. * First-line: Ceftriaxone 1 g IV daily for up to 7 days, or Norfloxacin (oral) 400 mg PO BID if patient can tolerate oral intake and has no quinolone resistance. 4. Proton Pump Inhibitors (PPIs): Standard care for UGI bleeding, though their role in variceal bleeding is less direct, they help with potential co-existing peptic injury or erosions. * Dose: Pantoprazole 80 mg IV bolus, then 8 mg/hour continuous infusion.

• Stabilization (Early Management Priorities):
  1. Urgent Endoscopy: Performed within 12 hours of presentation after initial resuscitation and pharmacologic treatment.
     • Esophageal Varices: Endoscopic Variceal Ligation (EVL) is the preferred treatment. Banding varices until they are obliterated.
     • Gastric Varices:
       • GOV1: EVL may be effective.
       • GOV2 or IGV1 (fundal varices): Cyanoacrylate glue injection (endoscopic variceal obturation) is preferred.
       • Sclerotherapy (e.g., with ethanolamine oleate) is an alternative but less common, especially for esophageal varices where EVL is superior.
• Emergency (Crisis Management for Refractory Bleeding):
  1. Balloon Tamponade: (e.g., Sengstaken-Blakemore tube, Minnesota tube, Linton tube). Used as a temporary bridge to definitive treatment (endoscopy or TIPS) when bleeding cannot be controlled endoscopically or endoscopy is unavailable.
     • Mechanism: Direct compression of bleeding varices.
     • Duration: Max 24 hours due to high risk of complications (aspiration, esophageal rupture, necrosis). Intubation is often required before placement.
  2. Transjugular Intrahepatic Portosystemic Shunt (TIPS): For patients with uncontrolled bleeding despite endoscopic and pharmacologic therapy, or for early rebleeding.
     • Mechanism: Creates a direct shunt between the portal and hepatic veins, reducing portal pressure.
     • Timing: "Pre-emptive" TIPS (within 72 hours, ideally <24 hours) may be considered in high-risk patients (Child-Pugh C with MELD score ≤18 or Child-Pugh B with active bleeding at endoscopy despite vasoactive drugs).

Chronic Management

Aims to prevent rebleeding and manage underlying portal hypertension. - Pharmacological: * Non-selective Beta-Blockers (NSBBs): Primary therapy for secondary prophylaxis (preventing rebleeding). * Mechanism: Reduce portal pressure by decreasing cardiac output (beta-1 blockade) and splanchnic vasoconstriction (beta-2 blockade). * Agents: Propranolol, Nadolol, Carvedilol. * Dosing: Start at low dose and titrate every 2-3 days to the maximum tolerated dose or until heart rate reduction of 25% from baseline or to 55-60 bpm, provided SBP >90 mmHg. * Propranolol: Initial 20-40 mg PO BID. Max 160 mg BID. * Nadolol: Initial 20-40 mg PO QD. Max 80 mg QD. * Carvedilol: Initial 6.25 mg PO QD. Max 25 mg QD. (May be more effective than other NSBBs due to additional alpha-1 blockade, but can cause more hypotension). * Duration: Indefinite. - Non-pharmacological: * Endoscopic Variceal Ligation (EVL): For secondary prophylaxis, typically performed in combination with NSBBs. * Schedule: Initial EVL sessions every 1-2 weeks until varices are obliterated, then surveillance endoscopy every 1-3 months for first year, then annually. * TIPS (Transjugular Intrahepatic Portosystemic Shunt): * Indications: Recurrent variceal bleeding despite optimal medical and endoscopic therapy (NSBBs + EVL), refractory ascites, or early pre-emptive TIPS in high-risk patients. * Shunt Surgery: Rarely performed due to high morbidity/mortality and availability of TIPS. Considered in highly selected patients who are not candidates for TIPS. * Liver Transplantation: Definitive treatment for underlying liver disease. Evaluation should be initiated for appropriate candidates. - Monitoring: * Regular Endoscopic Surveillance: Post-EVL, follow-up endoscopy is needed to ensure variceal obliteration and detect new or recurrent varices. Frequency depends on initial findings and previous treatment. * Clinical Monitoring: For signs of rebleeding, liver decompensation, hepatic encephalopathy. * Laboratory Monitoring: Regular LFTs, renal function, electrolytes, CBC to monitor liver disease progression and complications.

Treatment Algorithms

• First-Line (Acute Variceal Bleeding):
  1. Resuscitation: IV access, fluids (target SBP 90-100 mmHg), pRBCs (target Hb 7-8 g/dL), correct severe coagulopathy/thrombocytopenia if indicated. Airway protection as needed.
  2. Pharmacologic: IV vasoactive drug (Octreotide/Terlipressin) + IV antibiotic prophylaxis (Ceftriaxone).
  3. Urgent Endoscopy (within 12 hours):
     • Esophageal Varices: EVL.
     • Gastric Varices (GOV2/IGV1): Cyanoacrylate glue injection.
• Second-Line (Acute, if Endoscopy Fails or is Unavailable):
  1. Balloon Tamponade: Temporary measure (max 24h) while arranging definitive treatment (repeat endoscopy or TIPS).
  2. TIPS: For uncontrolled bleeding (failure to achieve initial hemostasis) or very early rebleeding despite optimal medical and endoscopic therapy.
• Refractory Cases (Recurrent bleeding despite chronic management):
  1. TIPS: Primary treatment for secondary prophylaxis failure (rebleeding despite NSBBs + EVL).
  2. Repeat EVL/Glue Injection: If accessible and amenable to further endoscopic therapy.
  3. Liver Transplantation: Evaluate suitable candidates.

Complications

• Common:
  • Rebleeding: Very common without adequate prophylaxis.
  • Hepatic Encephalopathy: Precipitated by blood in the GI tract (protein load) and often by TIPS.
  • Bacterial Infections: Spontaneous bacterial peritonitis (SBP), pneumonia, urinary tract infections, bacteremia.
  • Acute Kidney Injury/Hepatorenal Syndrome (HRS): Often triggered by hypovolemia, infection, or aggressive diuretic use.
  • Aspiration Pneumonia: Due to hematemesis, especially with impaired consciousness or during endoscopic procedures.
• Serious:
  • Hemorrhagic Shock: Leading to multi-organ failure and death.
  • Esophageal Perforation/Rupture: Rare but severe complication of EVL or balloon tamponade.
  • Ischemic Complications: From vasoactive drugs (Terlipressin especially).
• Long-term:
  • Chronic Anemia: Due to persistent low-grade bleeding or repeated acute bleeds.
  • Variceal Recurrence: Despite treatment, varices can recur.
  • Complications of Liver Disease Progression: Ascites, SBP, HRS, hepatic encephalopathy, hepatocellular carcinoma.

Prognosis

• Factors:
  • Severity of Liver Disease: Child-Pugh score, MELD score are strong predictors of mortality. Child-Pugh class C, MELD >18, or active alcoholism associated with worse outcomes.
  • Severity of Bleed: Initial large volume bleed, failure to achieve initial hemostasis.
  • Presence of Complications: Bacterial infection, acute kidney injury/HRS, hepatic encephalopathy.
  • Rebleeding: Subsequent bleeding episodes carry higher mortality.
• Survival:
  • Mortality from a first variceal bleed is approximately 15-20% at 6 weeks.
  • Patients who survive the initial bleed have a 60-70% risk of rebleeding within the first year without prophylaxis.
  • Overall 1-year survival rates are significantly lower for patients who experience a variceal bleed compared to those with cirrhosis who do not bleed.
• Quality of Life:
  • Significantly impacted by recurrent bleeding episodes, hospitalizations, side effects of medications, and the chronic nature of underlying liver disease and its complications (e.g., hepatic encephalopathy, ascites).

Prevention

Primary Prevention (Preventing the first bleed)

For patients with known cirrhosis but no prior variceal bleed. - Screening Endoscopy: All patients with cirrhosis should undergo screening EGD to detect varices. - Patients without Varices or Small Varices without Red Signs: * No specific intervention for bleeding prevention. * Repeat endoscopy every 2-3 years if compensated cirrhosis, or yearly if decompensated. - Patients with Medium/Large Varices or Small Varices with Red Signs: * Non-selective Beta-Blockers (NSBBs): First-line for primary prophylaxis. * Agents: Propranolol, Nadolol, Carvedilol. * Dosing: Titrate to maximum tolerated dose or target heart rate reduction (25% from baseline or to 55-60 bpm), maintaining SBP >90 mmHg. * Rationale: Reduce portal pressure, thereby reducing variceal size and risk of rupture. * Endoscopic Variceal Ligation (EVL): Alternative to NSBBs if contraindications or intolerance exist (e.g., severe asthma, symptomatic bradycardia, hypotension). * Rationale: Physically obliterates varices. * Schedule: EVL sessions typically every 2-4 weeks until varices are eradicated, then surveillance.

Secondary Prevention (Preventing rebleeding after a first bleed)

• Combination Therapy: NSBBs + EVL is the gold standard for secondary prophylaxis.
  • NSBBs: Start as soon as patient is stable (within hours to days of acute bleed). Continue indefinitely.
  • EVL: Start 1-2 weeks after the acute bleed, with subsequent sessions every 1-2 weeks until variceal obliteration. Then surveillance endoscopy.
• TIPS (Transjugular Intrahepatic Portosystemic Shunt):
  • Considered for patients who fail secondary prophylaxis (rebleeding despite NSBBs + EVL) or as "pre-emptive" TIPS in very high-risk patients (Child-Pugh C with MELD ≤18, or Child-Pugh B with active bleeding at endoscopy despite vasoactive drugs).

Tertiary Prevention (Preventing complications, maximizing function)

• Manage Underlying Liver Disease: Treat the cause of cirrhosis (e.g., antiviral therapy for hepatitis B/C, abstinence from alcohol, weight loss for NAFLD).
• Manage Complications of Cirrhosis:
  • Ascites: Diuretics, sodium restriction.
  • Hepatic Encephalopathy: Lactulose, rifaximin.
  • Infections: Prophylaxis if indicated (e.g., Norfloxacin for SBP recurrence).
• Avoid Hepatotoxins: Alcohol, certain medications.

Special Populations

• Pediatric:
  • Etiology: Portal hypertension in children often results from extrahepatic portal vein obstruction (EHPVO) or biliary atresia, rather than cirrhosis from adult causes.
  • Management: Principles are similar (resuscitation, vasoactive drugs, endoscopy). Doses are weight-based. EVL is effective. Sclerotherapy may be preferred in very young children or small lumens. Surgical shunts or splenic devascularization procedures may be more frequently considered in EHPVO due to good liver function.
• Geriatric:
  • Comorbidities: Higher prevalence of cardiovascular disease, renal insufficiency, and polypharmacy. This impacts fluid resuscitation targets, tolerance to vasoactive drugs (Terlipressin) and NSBBs.
  • Fragile Hemodynamics: Less reserve, higher risk of complications from hypotension or over-resuscitation.
  • Cognitive Impairment: May make history taking difficult and increase risk of aspiration.
• Pregnancy:
  • Rare: Cirrhosis in pregnancy is uncommon, but variceal bleeding can be devastating for mother and fetus.
  • Management: Endoscopy is safe in all trimesters. EVL is preferred. Terlipressin is contraindicated due to oxytocic effects; Octreotide is generally considered safer. TIPS is a last resort due to risks. Delivery mode is often C-section if varices are large and bleeding risk high.
• Comorbidities:
  • Renal Failure/HRS: Aggressive management of volume status, prevention of infection. Terlipressin may have a renal protective effect in HRS, but careful monitoring is needed.
  • Cardiac Disease: More conservative fluid resuscitation targets (e.g., slightly lower Hb target) to avoid precipitating heart failure. Careful use of NSBBs.
  • Diabetes: Octreotide can affect blood glucose levels; monitor closely.

Clinical Pearls

• Diagnostic:
  • Always suspect variceal bleeding in patients with known or suspected cirrhosis presenting with UGI bleeding.
  • Look for stigmata of liver disease on physical exam.
  • Hematochezia in a cirrhotic patient can be from massive variceal bleed; don't assume lower GI source without endoscopy.
• Treatment:
  • Early initiation of antibiotic prophylaxis is critical and saves lives. Do not delay.
  • Conservative fluid resuscitation and transfusion (target Hb 7-8 g/dL) is generally preferred to avoid increasing portal pressure.
  • Vasoactive drugs (Octreotide/Terlipressin) should be started immediately upon suspicion, even before endoscopy, and continued for 2-5 days post-hemostasis.
  • Endoscopy within 12 hours is paramount for diagnosis and definitive treatment.
  • Balloon tamponade is a temporary measure; plan for definitive treatment immediately after placement.
  • Consider TIPS early in high-risk patients or those failing initial therapy.
• Pitfalls:
  • Delayed diagnosis and treatment.
  • Over-resuscitation with fluids/blood, leading to increased portal pressure and worsening bleeding.
  • Failure to provide antibiotic prophylaxis.
  • Underestimation of the severity of the bleed or underlying liver disease.
  • Using beta-blockers without careful titration or in hemodynamically unstable patients.

Recent Updates

• Guidelines:
  • Baveno VII Consensus (2021): Updated recommendations for diagnosis and management of portal hypertension-related complications, including refined HVPG thresholds and expanded role for non-invasive risk stratification. Emphasizes individualized medicine based on risk profiles.
  • AASLD Guidelines (2017 & subsequent updates): Provide comprehensive, evidence-based recommendations for the treatment of portal hypertensive bleeding.
• Evidence:
  • Carvedilol in Primary Prophylaxis: Growing evidence supports carvedilol as an effective and potentially superior NSBB for primary prophylaxis, offering additional alpha-1 blockade.
  • Pre-emptive TIPS: Further studies support the use of "early" or "pre-emptive" TIPS within 72 hours (ideally <24 hours) for high-risk patients (Child-Pugh C with MELD ≤18, or Child-Pugh B with active bleeding at endoscopy) to improve survival and reduce rebleeding.
  • Role of Vasoactive Drugs: Continued emphasis on early initiation and duration of vasoactive agents (2-5 days) to reduce rebleeding and mortality.
• Controversies:
  • Optimal Timing of TIPS: While "pre-emptive" TIPS is gaining traction, the precise timing and selection criteria for intermediate-risk patients remain an area of ongoing research and debate.
  • Role of Non-invasive Assessment: Efforts continue to develop reliable non-invasive methods (e.g., liver stiffness measurement by elastography, platelet count/spleen diameter ratio) to identify patients at high risk for varices, potentially reducing the need for universal screening endoscopy.

Key References

• Guidelines:
  • De Franchis, R., et al. (2022). Baveno VII – Renewing consensus in portal hypertension. Journal of Hepatology, 76(4), 959-974. (The latest Baveno consensus provides comprehensive recommendations).
  • Garcia-Tsao, G., et al. (2017). AASLD practice guidance: The management of variceal hemorrhage in patients with cirrhosis. Hepatology, 65(3), 1022-1039.
• Studies:
  • Villanueva, C., et al. (2013). Terlipressin plus albumin for the prevention of hepatorenal syndrome in patients with cirrhosis and spontaneous bacterial peritonitis. New England Journal of Medicine, 368(19), 1827-1830. (Demonstrates benefit of vasoactive agents in HRS).
  • García-Pagán, J. C., et al. (2010). Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) in patients with cirrhosis and acute variceal bleeding. New England Journal of Medicine, 362(24), 2374-2380. (Landmark study for pre-emptive TIPS).
  • Garg, P., et al. (2019). Carvedilol versus Endoscopic Variceal Ligation for the Primary Prophylaxis of Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 17(2), 270-280.e1. (Evidence for carvedilol).
• Reviews:
  • D'Amico, G., et al. (2010). Pharmacological treatment of portal hypertension. Seminars in Liver Disease, 30(2), 114-124.
  • Northup, P. G., et al. (2019). Prevention and management of gastroesophageal varices in patients with cirrhosis. American Journal of Gastroenterology, 114(5), 720-735.